Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Arch Therapeutics Inc (ARTH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 63,928
  • Shares Outstanding, K 159,820
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,790 K
  • 36-Month Beta 0.70
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 28.41
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.01
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 09/27/18
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/18
See More
  • Average Estimate -0.01
  • Number of Estimates 3
  • High Estimate -0.01
  • Low Estimate -0.01
  • Prior Year -0.01
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3900 +2.56%
on 09/19/18
0.4850 -17.53%
on 09/05/18
-0.0050 (-1.23%)
since 08/21/18
3-Month
0.3500 +14.29%
on 08/15/18
0.6900 -42.03%
on 06/28/18
-0.0550 (-12.09%)
since 06/21/18
52-Week
0.2500 +60.00%
on 12/18/17
0.8400 -52.38%
on 10/02/17
-0.3750 (-48.39%)
since 09/21/17

Most Recent Stories

More News
Arch Therapeutics Reports Topline Results from Skin Sensitization Study of AC5

Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, today announced topline data for its irritation/sensitization patch...

ARTH : 0.4000 (unch)
Arch Therapeutics to Provide Corporate Update at the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018

Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the H.C. Wainwright...

ARTH : 0.4000 (unch)
Arch Therapeutics Appoints Healthcare Industry Executive Punit Dhillon to Board of Directors

Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device(TM) ("AC5(TM)"), today announced the appointment of Punit Dhillon, former President & CEO...

NMUS : 0.2950 (-2.03%)
ONCS : 1.40 (+0.72%)
EMH.VN : 4.970 (+0.40%)
ARTH : 0.4000 (unch)
Arch Therapeutics, Inc. $4.5 Million Registered Direct Offering

Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), a developer of innovative materials as hemostatic and wound care devices, today announced the pricing of registered direct offering of 9.1...

ARTH : 0.4000 (unch)
Arch Therapeutics Provides Skin Sensitization Study Status Update

Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, provided an update today in which it announced that in the recently...

ARTH : 0.4000 (unch)
Arch Therapeutics Completes Enrollment and Initiates Dosing in Skin Sensitization Study

Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, announced today that it has completed enrollment for its human skin...

ARTH : 0.4000 (unch)
Arch Therapeutics to Provide Corporate Update at the 8th LD Micro Invitational on Monday, June 4, 2018

Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the 8 LD Micro Invitational....

ARTH : 0.4000 (unch)
Arch Therapeutics Provides Update on Study Initiation and 510(k)

Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, today announced that it will initiate the previously disclosed study...

ARTH : 0.4000 (unch)
Arch Therapeutics Provides Update on 510(k)

Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, today announced that it has utilized the Food and Drug Administration's...

ARTH : 0.4000 (unch)
OTCQX And OTCQB Companies to Present At 2018 ROTH Conference

OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today unveiled the list of OTCQX® Best Market and OTCQB® Venture Market presenting companies...

KSHB : 5.8300 (+4.29%)
EVLLF : 0.8249 (+4.42%)
OPRX : 16.57 (-7.84%)
DMIFF : 0.2630 (+1.94%)
CORVF : 2.4878 (+0.31%)
IMPZY : 0.7400 (-8.07%)
CHPE : 19.2500 (-1.18%)
CBWTF : 0.9100 (-3.70%)
ATMS : 0.6551 (-13.24%)
RSSS : 2.2000 (unch)
FSSN : 0.1500 (+13.38%)
MSRT : 0.1460 (+5.04%)
GPVRF : 0.4190 (+6.08%)
QBIO : 2.9700 (-0.34%)
SNYR : 0.2575 (-1.90%)
ACBFF : 9.2218 (-2.83%)
CVSI : 5.0900 (-5.39%)
RSASF : 0.2400 (+33.78%)
COSM : 4.4500 (-14.26%)
GRWG : 4.2150 (+2.80%)
GTBP : 2.1000 (+5.00%)
ZYXI : 3.1000 (+0.32%)
PURE : 0.6380 (+1.43%)
CXDO : 2.1000 (+5.00%)
BCTXF : 0.1149 (+14.90%)
TAOIF : 0.3033 (-0.07%)
BNOEF : 0.3900 (+2.09%)
NMKEF : 0.6214 (+13.35%)
CNNRF : 5.2450 (-3.71%)
ZEST : 1.1200 (unch)
HEOFF : 0.8374 (-1.48%)
ITHUF : 6.1300 (-4.96%)
COTQF : 0.1394 (-2.92%)
OTCM : 28.2000 (-1.91%)
DCTH : 4.3500 (-39.67%)
AEYE : 8.63 (+4.48%)
VFFIF : 6.1209 (+3.74%)
TITXF : 0.1930 (-1.03%)
NMGRF : 0.2267 (-0.92%)
GLDLF : 0.6520 (+0.31%)
SNNVF : 4.4774 (+0.62%)
IWSY : 1.0000 (+0.20%)
ARTH : 0.4000 (unch)
IRNC : 0.6000 (unch)
PNGZF : 0.1500 (+7.14%)
NTSFF : 0.6239 (+0.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ARTH with:

Key Turning Points

2nd Resistance Point 0.4331
1st Resistance Point 0.4165
Last Price 0.4000
1st Support Level 0.3869
2nd Support Level 0.3739

See More

52-Week High 0.8400
Fibonacci 61.8% 0.6146
Fibonacci 50% 0.5450
Fibonacci 38.2% 0.4754
Last Price 0.4000
52-Week Low 0.2500

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar